Clinical Trial Update: Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TAK-700 for safety and efficacy in nonmetastatic castration-resistant prostate cancer with rising PSA has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmetastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• TAK-700 (Orteronel)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED